PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C1704231|leptomeningeal metastases |
| Sentences | 5 |
| PubMedID- 21547396 | The incidence of leptomeningeal metastases (lm) in patients with breast cancer (bc) is increasing as a result of increased screening and improved patient survival. |
| PubMedID- 25789061 | Furthermore, a pilot study (n=15) indicated that bevacizumab significantly decreases csf vegf levels over time, resulting in clinical, imaging and csf responses, or stable disease in 54–73% of leptomeningeal metastases patients with breast cancer, lung cancer, or melanoma (10,23). |
| PubMedID- 23593093 | Although several treatment options are available for breast cancer patients with leptomeningeal metastases with possibility for long-term response, reported outcomes are highly variable and long-term response is uncommon. |
| PubMedID- 25223975 | Background: leptomeningeal metastases occur in 2%-5% of patients with breast cancer and have an exceptionally poor prognosis. |
| PubMedID- 25886304 | Axial t1-weighted mri indicated a diffuse linear enhancement in the cerebellar sulcus, suggesting leptomeningeal metastases of breast cancer (figure 1c). |
Page: 1